HIV-associated mania treated with electroconvulsive therapy and highly-active antiretroviral therapy

Psychosomatics

Volumn 47, Issue 2, 2006, Pages 170-174

  Ferrando, Stephen J ^a,b   Nims, Chloe ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BROMOCRIPTINE; CHLORDIAZEPOXIDE; HALOPERIDOL; LAMIVUDINE; LAMOTRIGINE; LOPINAVIR; LORAZEPAM; MIDAZOLAM; OLANZAPINE; RITONAVIR; ZIDOVUDINE;

ADULT; AGITATION; ARTICLE; BIPOLAR DISORDER; CASE REPORT; DELIRIUM; ELECTROCONVULSIVE THERAPY; FEVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IRRITABILITY; LYMPHOCYTE CULTURE; LYMPHOCYTOPENIA; MALE; MANIA; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; TACHYCARDIA; VIRUS LOAD;

EID: 33644784070     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.psy.47.2.170     Document Type: Letter

References (43)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860
2. Centers for Disease Control and Prevention (CDC): HIV Prevention Strategic Plan Through 2005. Atlanta, GA, CDC, Jan 2001
3. Centers for Disease Control and Prevention (CDC): HIV and AIDS: United States, 1981-2001. MMWR 2001; 50:430-434
4. St. Louis ME, Rauch KJ, Petersen LR, et al: Seroprevalence rates of human immunodeficiency virus infection at sentinel hospitals in the United States: The Sentinel Hospital Surveillance Group. N Engl J Med 1990; 323:213-218
5. Janssen RS, St Louis ME, Satten GA, et al: HIV infection among patients in U.S. care hospitals: strategies for the counseling and testing of the hospital patients: The Hospital HIV Surveillance Group. N Engl J Med 1992; 327:445-452
6. American Academy of Neurology AIDS Task Force: Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus Type-1 (HIV-1) infection. Neurology 1991; 41:778-785
7. Wilkie FL, Goodkin K, Eisdorfer C, et al: Mild cognitive impairment and risk of mortality in HIV-1 infection. J Neuropsychiatry Clin Neurosci 1998; 10:125-132
8. Sacktor NC, Bacellar H, Hoover DR, et al: Psychomotor slowing in HIV infection: a predictor of dementia, AIDS, and death. J Neurovirol 1996; 2:404-410
9. Lipton SA: Neuronal injury associated with HIV-1 and potential treatment with calcium-channel and NMDA antagonists. Dev Neurosci 1994; 16:145-151
10. Letendre SL, McCutchan JA, Childers ME, et al: Enhancing anti-retroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol 2004; 56:416-423
11. Marra CM, Lockhart D, Zunt JR, et al: Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy. Neurology 2003; 60:1388-1390
12. Sacktor N, Lyles RH, Skolasky R, et al: Multicenter AIDS Cohort Study. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study. 1990-1998. Neurology 2001; 56:257-260
13. Gisslen M, Hagberg L, Svennerholm B, et al: HIV-1 RNA is not detectable in the cerebrospinal fluid during antiretroviral combination therapy. AIDS 1997; 11:1194
14. Filippi C, Sze G, Farber SJ, et al: Regression of HIV encephalopathy and basal-ganglia signal-intensity abnormality at MR imaging in patients with AIDS after the initiation of protease-inhibitor therapy. Radiology 1998; 206:491-498
15. Chang L, Ernst T, Leonido-Yee M, et al: Highly active antiretroviral therapy reverses brain-metabolite abnormalities in mild HIV dementia. Neurology 1999; 53:782-789
16. Tozzi V, Balestra P, Galgani S, et al: Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment. AIDS 1999; 13:1889-1897
17. Ferrando SJ, Rabkin JG, van Gorp WG, et al: Longitudinal improvement in psychomotor processing speed is associated with potent combination antiretroviral therapy in HIV-1 infection. J Neuropsychiatry Clin Neurosci 2003; 15:208-214
18. Ferrando S, van Gorp W, McElhiney M, et al: Highly active antiretroviral treatment (HAART) in HIV infection: benefits for neuropsychological function. AIDS 1998; 12:F65-F70
19. Hinkin CH, Hardy DJ, Mason KL, et al: Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS 2004;18(suppl 1):S19-S25
20. Rabkin JG, McElhiney M, Ferrando SJ, et al: Predictors of employment in men with HIV/AIDS: a longitudinal study. Psychosom Med 2004; 66:72-78
21. Kieburtz K, Zettelmaier AE, Ketonen L, et al: Manic syndrome in AIDS. Am J Psychiatry 1991; 148:1068-1070
22. McGowan I, Potter M, George RJ, et al: HIV encephalopathy presenting as hypomania. Genitourin Med 1991; 67:420-424
23. Lyketsos CG, Hanson AL, Fishman M, et al: Manic syndrome early and late in the course of HIV. Am J Psychiatry 1993; 150:326-327
24. Lyketsos GC, Schwartz J, Fishman M, et al: AIDS mania. J Neuropsychiatry Clin Neurosci 1997; 9:277-279
25. Ellen SR, Judd FK, Mijch AM, et al: Secondary mania in patients with HIV infection. Aust N Z J Psychiatry 1999; 33:353-360
26. Krauthammer C, Klerman GL: Secondary mania. Arch Gen Psychiatry 1978; 35:1333-1339
27. Navia BA, Jordan BD, Price RW: The AIDS dementia complex, I: clinical features. Ann Neurol 1986; 19:517-524
28. Fink M, Taylor MA: The many varieties of catatonia. Eur Arch Psychiatry Clin Neurosci 2001; 251(suppl 1):8-13
29. Bernstein WB, Scherokman B: Neuroleptic malignant syndrome in a patient with acquired immunodeficiency syndrome. Acta Neurol Scand 1986; 73:636-637
30. Breitbart W, Marotta RF, Call P: AIDS and neuroleptic malignant syndrome. Lancet 1988; 2:1488-1489
31. Lazarus A: EPS, NMS, and AIDS. Biol Psychiatry 1990; 28:551-552
32. Sewell DD, Jeste DV, McAdams LA, et al: Neuroleptic treatment of HIV-associated psychosis: HNRC Group. Neuropsychopharmacology 1994; 10:223-229
33. Ferrando S, Eisendrath S: Adverse neuropsychiatric effects of dopamine-antagonist medications: misdiagnosis in the medical setting. Psychosomatics 1991; 32:426-432
34. Manser TJ, Warner JF: Neuroleptic malignant syndrome associated with prochlorperazine. South Med J 1990; 83:73-74
35. Edelstein HE, Chirurgi VA, Gloudeman MW, et al: Adverse reactions to phenothiazine antiemetics in AIDS. DICP (Ann Pharmacother) 1991; 25:1007
36. Levenson J: Neuroleptic malignant syndrome. Am J Psychiatry 1985; 142:1137-1145
37. Meyer JM, Marsh J, Simpson G: Differential sensitivities to risperidone and olanzapine in a human-immunodeficiency-virus patient. Biol Psychiatry 1998; 44:791-794
38. Kelly DV, Beique LC, Bowmer MI: Extrapyramidal symptoms with ritonavir/indinavir plus risperidone. Ann Pharmacother 2002; 36:827-830
39. Mijch AM, Judd FK, Lyketsos CG, et al: Secondary mania in patients with HIV infection: are antiretrovirals protective? J Neuropsychiatry Clin Neurosci 1999; 11:475-480
40. Schaerf FW, Miller RR, Lipsey JR, et al: ECT for major depression in four patients infected with human immunodeficiency virus. Am J Psychiatry 1989; 146:782-784
41. Kessing L, LaBianca JH, Bolwig TG: HIV-induced stupor treated with ECT. Convuls Ther 1994; 10:232-235
42. Mukherjee S, Debsikdar V: Unmodified electroconvulsive therapy of acute mania: a retrospective naturalistic study. Convuls Ther 1992; 8:5-11
43. Davis JM, Janicak PG, Sakkas P, et al: Electroconvulsive therapy in the treatment of the neuroleptic malignant syndrome. Convuls Ther 1991; 7:111-120